ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2010
Targeted therapy for advanced thymic tumors.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Thymic epithelial tumors: a narrative review of diagnostic and therapeutic advances.Translational cancer research · 2026Review
- Low GBX2 expression is associated with histological type B thymoma: a multi-omics analysis.Discover oncology · 2026Article
- A phase II study of buparlisib in relapsed or refractory thymomas.Frontiers in oncology · 2022Article
- Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion.The journal of gene medicine · 2021Article
- PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
- Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?Journal of thoracic disease · 2016Article
- ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymoma.Oncogenesis · 2014Article
- Advances in thymic carcinoma diagnosis and treatment: a review of literature.Medical oncology (Northwood, London, England) · 2014Review
- Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.Targeted oncology · 2012Article
- Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.World journal of clinical oncology · 2012Article
- Acute respiratory distress due to thymoma in a patient treated with TK inhibitor: a case report and review of the current treatment options.Case reports in oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The use of targeted therapies for the treatment of thymic malignancies is documented in the literature. However, only a few drugs have undergone evaluation in phase II trials. Most of the evidence for the benefit of biologic therapies for thymic malignancies is in the form of case reports and small case series. No major activity has been observed with any agent so far, likely due to the lack of selection of patients for targeted therapies and the small numbers studied. A better understanding of the biology of these tumors will be essential in furthering the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.